Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET

Medicine (United States)

Volumn 96, Issue 49, 2017, Pages

  Zheng, Xiangqin ^a   Lin, Danmei ^a   Zhang, Yulong ^a   Lin, Yuan ^a   Song, Jianrong ^a   Li, Suyu ^a   Sun, Yan ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

in vitro fertilization embryo transfer; inositol; intracytoplasmic sperm injection; ovulation induction; pregnancy rate

Indexed keywords

ESTRADIOL; FOLIC ACID; INOSITOL;

ABORTION; COMBINATION DRUG THERAPY; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; META ANALYSIS; MONOTHERAPY; OOCYTE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; DIETARY SUPPLEMENT; DRUG EFFECTS; IN VITRO FERTILIZATION; PREGNANCY; PROCEDURES;

ADULT; DIETARY SUPPLEMENTS; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; INOSITOL; OOCYTES; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 85038641683     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000008842     Document Type: Review

References (33)

1. Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci 2013; 17: 3095-102.
2. Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 508-13.
3. Unfer V, CarlomagnoG, Rizzo P, et al. Myo-inositol rather than D-chiroinositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011; 15: 452-7.
4. Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the International Consensus Conference on myo-inositol and D-chiroinositol in obstetrics and gynecology-assisted reproduction technology. Gynecol Endocrinol 2015; 31: 441-6.
5. Facchinetti F, Bizzarri M, Benvenga S, et al. Results from the International Consensus Conference on Myo-inositol and d-chiroinositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol 2015; 195: 72-6.
6. Granata R, Settanni F, Biancone L, et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic (-cells and human islets: involvement of 3', 5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 2007; 148: 512-29.
7. Burghen GA, Givens JR, Kitabchi AE. Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease. J Clin Endocrinol Metab 1980; 50: 113-6.
8. Azziz R, EhrmannD, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial 1. J Clin Endocrinol Metab 2001; 86: 1626-32.
9. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum ReprodV 17 2002; 1729-37.
10. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev V 5 2012; CD003053. doi: 10.1002/14651858.
11. Zheng X, Liu Z, Zhang Y, et al. Relationship between myo-inositol supplementary and gestational diabetes mellitus: a meta-analysis. Medicine 2015; 94: e1604.
12. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. J Diabetes Res 2002; 3: 47-60.
13. Colazingari S, Treglia M, Najjar R, et al. The combined therapy myoinositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 2013; 288: 1405-11.
14. Chiu TTY, Rogers MS, Law ELK, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002; 17: 1591-6.
15. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750-4.
16. Ciotta L, Stracquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011; 15: 509-14.
17. Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012; 10: 1.
18. Caprio F, D'Eufemia MD, Trotta C, et al. Myo-inositol therapy for poorresponders during IVF: a prospective controlled observational trial. J Ovarian Res 2015; 8: 1.
19. Pacchiarotti A, Carlomagno G, Antonini G, et al. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol 2016; 32: 69-73.
20. Emekçi Özay Ö, Özay AC, Çaǧliyan E, et al. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecol Endocrinol 2017; 1-5.
21. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
23. Pacchiarotti A. Antioxidative capacity of melatonin in follicular fluid of aged IVF patients: beneficial effects on oocytes and embryo. J Gynecol Neonatal Biol 2015; 1: 1-5.
24. Andersen AN, Witjes H, Gordon K, et al. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011; 26: 3413-23.
25. Van Loendersloot LL, VanWely M, Limpens J, et al. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 577-89.
26. Chiu TTY, Tam PPL. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 1992; 9: 524-30.
27. Chiu TTY, Rogers MS, Briton-Jones C, et al. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003; 18: 408-16.
28. Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28: 509-15.
29. Papaleo E, Unfer V, Baillargeon JP, et al. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009; 147: 120-3.
30. Taieb J, Grynberg M, Pierre A, et al. FSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells. Mol Endocrinol 2011; 25: 645-55.
31. Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril 2009; 92: 328-43.
32. Buckett WM. A review andmeta-analysis of prospective trials comparing different catheters used for embryo transfer. Fertil Steril 2006; 85: 728-34.
33. Al-Inany HG, Abou-Setta AM, Aboulghar MA, et al. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol 2009; 25: 372-8.